BioNTech schimba directia - 27 martie 2023: Diferență între versiuni

<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat] ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa [[actiuni]] proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>